NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE), has entered into a research collaboration with Quotient Therapeutics, a Cambridge, Massachusetts-based biotech firm. The partnership will focus on analyzing somatic mutations in diseased patient tissue, with a goal of uncovering new therapeutic approaches for cardiovascular and renal diseases.
Established in 2022 by Flagship Pioneering, a venture capital firm specializing in life sciences, Quotient Therapeutics is renowned for its somatic genomics platform. This platform is designed to uncover new genetic-disease associations and has attracted Pfizer’s interest as a means to bolster its research capabilities.
The collaboration will be conducted in conjunction with Flagship Medicines, the drug development division of Flagship Pioneering. This deal is an extension of an existing partnership framework between Pfizer and Flagship, highlighting a shared commitment to innovation in biotechnology.
In July 2023, both companies had already laid the groundwork for this collaboration by investing a combined upfront amount of USD 100 million to develop 10 single-asset programs. Pfizer has further pledged up to USD 700 million in milestone payments for Flagship and its associated companies, demonstrating a significant vote of confidence in Flagship’s ecosystem of over 40 healthcare and biotech entities.
The latest agreement, signed in June 2024, marks the first collaboration between Pfizer and ProFound Therapeutics, Flagship’s subsidiary focused on obesity treatments. This progressive approach to drug discovery and development underscores Pfizer’s dedication to advancing healthcare solutions through strategic partnerships with innovative biotech companies.- Flcube.com
